| 前收市價 | 43.55 |
| 開市 | 43.55 |
| 買盤 | 44.50 |
| 賣出價 | 49.50 |
| 拍板 | 170.00 |
| 到期日 | 2026-01-16 |
| 今日波幅 | 43.55 - 43.55 |
| 合同範圍 | 無 |
| 成交量 | |
| 未平倉合約 | 無 |
BenzingaPfizer Advances On Its Cancer Journey
On Saturday, Pfizer Inc (NYSE: PFE) presented positive trial data for experimental drug designed for patients suffering from cancer cachexia during the European Society for Medical Oncology 2024 Congress. Affecting as many as 9 million people across the globe, cancer cachexia is a life-threatening condition that causes cancer patients to lose appetite and consequently, weight. Paving The Way For The World’s First Treatment For Cancer Cachexia The mid-stage trial results showed that patients that
ZacksMerck's Keytruda Obtains its First FDA Approval for Mesothelioma
The FDA approves MRK's Keytruda for first-line treatment of malignant pleural mesothelioma. This marks Keytruda's first approval for the given indication.
ZacksInvestors Heavily Search Merck & Co., Inc. (MRK): Here is What You Need to Know
Merck (MRK) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
